RESTOR Trial
EARLY_PHASE1
194
about 3 years
65–90
1 site in TX
What this study is about
This trial is testing whether Everolimus or Rapamycin can safely slow down aging in older adults. The goal is to find a safe dose and timing for these drugs that can inhibit mTOR, a process related to aging, at levels similar to those seen in younger people. This research will also investigate how the best dose might differ between men and women.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Everolimus
- 3.Take Rapamycin
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
mTOR inhibitor, sirolimus
oral (Oral Tablet)
Primary: PD measure of inhibition of mTOR activity in blood cells - p-rpS6, Pharmacokinetics (PK) of mTOR inhibitor in blood
Secondary: PD measure of inhibition of mTOR activity in PBMCs Akt, PD measure of inhibition of mTOR activity in PBMCs, S6-kinase, PD measure of inhibition of mTOR activity in adipose (fat) cells Akt (Aim 2 only), PD measure of inhibition of mTOR activity in adipose cells, rpS6 (Aim 2 only), PD measure of inhibition of mTOR activity in fat cells (Aim 2 only) - pS6K, PD measure of inhibition of mTOR activity in muscle (Aim 2 only) - pS6K, PD measure of inhibition of mTOR activity in muscle Akt (Aim 2 only), PD measure of inhibition of mTOR activity in muscle rpS6 (Aim 2 only)